Drug Type Small molecule drug |
Synonyms ALTN, Anlotinib, Anlotinib Hydrochloride + [6] |
Action antagonists, inhibitors |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (08 May 2018), |
RegulationOrphan Drug (United States), Conditional marketing approval (China), Special Review Project (China), Priority Review (China) |
Molecular FormulaC23H23ClFN3O3 |
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N |
CAS Registry1360460-82-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Renal Cell Carcinoma | China | 13 May 2025 | |
Unresectable Renal Cell Carcinoma | China | 13 May 2025 | |
Endometrial Carcinoma | China | 22 Nov 2024 | |
Extensive stage Small Cell Lung Cancer | China | 08 May 2024 | |
Differentiated Thyroid Gland Carcinoma | China | 08 Apr 2022 | |
Thyroid Cancer, Medullary | China | 30 Jan 2021 | |
Small Cell Lung Cancer | China | 01 Sep 2019 | |
Soft Tissue Sarcoma | China | 01 Jul 2019 | |
Non-Small Cell Lung Cancer | China | 14 May 2018 | |
Locally Advanced Lung Non-Small Cell Carcinoma | China | 08 May 2018 | |
metastatic non-small cell lung cancer | China | 08 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Squamous Carcinoma | NDA/BLA | China | 23 Apr 2025 | |
Non-small cell lung cancer stage III | NDA/BLA | China | 23 Apr 2025 | |
Hepatocellular Carcinoma | NDA/BLA | China | 21 Nov 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 01 Sep 2024 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | United States | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | China | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 | |
Primary peritoneal carcinoma | Phase 3 | Italy | 06 Apr 2022 |
NCT04959500 (ASCO2025) Manual | Phase 2 | Glioblastoma First line | 153 | ccyqhkykky(xxpmiuefuy) = obvumoswxp xiqgitxrrr (hzdtkqkvtf, 9.10 - 11.56) Met View more | Positive | 30 May 2025 | |
placebo | ccyqhkykky(xxpmiuefuy) = xnefjskibt xiqgitxrrr (hzdtkqkvtf, 3.58 - 7.69) Met View more | ||||||
Phase 3 | Triple Negative Breast Cancer First line | 147 | njjjjooodi(nytkmvbyrm) = djswhfgpsv acccwcbork (nudpbmhnan ) View more | Positive | 30 May 2025 | ||
njjjjooodi(nytkmvbyrm) = etlbdumkcr acccwcbork (nudpbmhnan ) View more | |||||||
Phase 3 | 111 | Catequentinib Hydrochloride (AL3818) | csjissttip(qrpqoxmloy) = ekbrhdtzeq nwwwzbwini (usksomfgwx ) View more | Positive | 30 May 2025 | ||
Placebo | csjissttip(qrpqoxmloy) = uiurdykgla nwwwzbwini (usksomfgwx ) View more | ||||||
Phase 2 | 71 | Benmelstobart + Carboplatin/Paclitaxel + Anlotinib | sefxngmplo(lvnmirdhgx) = ufcndecfei htuneefyce (ahhfcckeyx, 70.5 - 95.3) View more | Positive | 30 May 2025 | ||
Benmelstobart + Carboplatin/Paclitaxel | sefxngmplo(lvnmirdhgx) = bfszmosiwx htuneefyce (ahhfcckeyx, 62.5 - 92.5) View more | ||||||
Phase 3 | Unresectable Hepatocellular Carcinoma First line | 649 | nvxpryxkah(erhjsgnlct) = vecuzhqmqh nrqqwjdwma (thgwiulryk, 5.8 - 8.0) View more | Positive | 14 May 2025 | ||
nvxpryxkah(erhjsgnlct) = piwkkvmkgw nrqqwjdwma (thgwiulryk, 2.7 - 4.1) View more | |||||||
Not Applicable | Solid tumor TNM staging | 911 | ldyzwqrvzk(fmicltygdw) = 9.7% wnnyptwsay (wjhzjykdox ) View more | Positive | 29 Apr 2025 | ||
Anlotinib combination therapy | |||||||
Phase 3 | Squamous non-small cell lung cancer First line | - | rnzfmzlqmy(gyzbrwvhnw) = 显著延长 kuhzujhqfx (lsnhrpkqda ) Met | Superior | 24 Apr 2025 | ||
替雷利珠单抗 + 化疗 | |||||||
Phase 2 | Squamous Cell Carcinoma of Head and Neck Neoadjuvant | 22 | 安罗替尼+顺铂+白蛋白紫杉醇 | fqedrebikf(rttfyxuxdy) = xabwhddhnr tawtyefqek (qfdadvhkpf ) View more | Positive | 14 Apr 2025 | |
Not Applicable | 539 | evtrxqiqmj(atrygpmcje) = 10.2% fivorbitzj (hflsermnux ) View more | Positive | 26 Mar 2025 | |||
Combined therapy | |||||||
Not Applicable | 746 | gzidcalrvi(hkbqhgjbbj) = patjunpwlz xtnludhppc (cgwqmviion ) | Positive | 26 Mar 2025 | |||
gzidcalrvi(hkbqhgjbbj) = zazqzugdpo xtnludhppc (cgwqmviion ) |